Estrella Immunopharma Receives Nasdaq Notice Over MVLS Shortfall

What Happened

• On September 1, 2026, Estrella Immunopharma, Inc. (NASDAQ: ESLA) filed an 8-K reporting that Nasdaq’s Listing Qualifications Department notified the company it is not in compliance with the market value of listed securities (MVLS) requirement under Nasdaq Listing Rule 5550(b)(2). Nasdaq found the company’s MVLS was below $35,000,000 for 30 consecutive business days from July 21, 2026 through August 31, 2026.
• The notice does not immediately affect trading; the company’s common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA. Nasdaq granted a 180-calendar-day compliance period, until March 1, 2027, for the company to regain compliance.

Key Details

• Letter date: September 1, 2026.
• MVLS threshold missed: $35,000,000; shortfall observed for July 21–August 31, 2026 (30 consecutive business days).
• Compliance deadline: 180 days (until March 1, 2027). To regain compliance, MVLS must close at $35,000,000 or more for at least 10 consecutive business days (Nasdaq may require a longer period, generally up to 20 business days).
• Alternative Nasdaq standards also not met per the notice: stockholders’ equity under Nasdaq Rule 5550(b)(1) ($2,500,000) and net income under Nasdaq Rule 5550(b)(3) ($500,000 in the most recent year or in two of the last three years).
• If compliance is not regained, Nasdaq will issue a delisting notice and the company may appeal to a Nasdaq hearings panel.

Why It Matters

• This notice starts a formal 180-day countdown during which Estrella must raise its MVLS to avoid a delisting process. Delisting could materially affect liquidity and market access for shareholders.
• There is no immediate trading suspension, but investors should monitor MVLS trends and company announcements about steps it will take to regain compliance. The company said it will evaluate available options, but there is no assurance it will succeed.